Apogee Therapeutics announced that its experimental anti-IL-13 antibody APG777 significantly reduced symptoms of moderate-to-severe atopic dermatitis in a Phase 2 trial. The drug achieved a 71% reduction in disease severity at week 16, outperforming established therapies like Dupixent and Ebglyss, with a potential advantage of less frequent dosing. The safety profile was consistent with existing agents. Apogee plans further dosing evaluations in upcoming studies, targeting regulatory approval.